No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Crism Therapeutics reported positive preclinical results for its Docetaxel-ChemoSeed implant on Tuesday, highlighting improved efficacy and tolerability compared with standard chemotherapy in a prostate cancer model.
The AIM-traded clinical-stage group said its implantable drug delivery technology demonstrated significant anti-tumour activity, a clear dose-response relationship and a favourable tolerability profile versus systemic docetaxel.
It said the study assessed tumour growth across multiple treatment groups, including standard of care and varying dose levels of Docetaxel-ChemoSeed.
Crism said tumour volumes were reduced across multiple dose levels, with the most pronounced effect showing a 58% reduction compared with standard treatment.
The data also showed stable body weight and no adverse tolerability effects or early terminations in ChemoSeed-treated groups, while systemic docetaxel was associated with reduced tolerability and multiple terminations.
The company said the findings supported its strategy of delivering chemotherapy locally and continuously to improve therapeutic outcomes while minimising systemic side effects.
Prostate cancer represented the second programme in Crism's pipeline using its ChemoSeed platform.
Its lead programme, Irinotecan-ChemoSeed in glioblastoma, remained on track for first patient dosing in an open-label phase two trial in the first half of 2026.
"The data clearly demonstrates that delivering chemotherapy locally and continuously, rather than intermittently and systemically, provides a much-needed improvement in therapeutic efficacy and tolerability," said chief scientific officer Chris McConville.
"The combination of tumour control, dose response and favourable tolerability observed in this study is encouraging and underpins our confidence in the potential of this technology as a localised treatment option for prostate cancer.
"These findings strongly support the continued development of Docetaxel-ChemoSeed and represent a meaningful step toward clinical evaluation."
At 1456 BST, shares in Crism Therapeutics Corporation were up 2.13% at 12p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate